Key facts
- This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Dec 2023, 16:35.
Patrick Lamy - 08 Dec 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- Senior Vice President, Commercial Strategy
- Issuer ticker
- AKRO
- Reported as of
- 08 Dec 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Dec 2023, 16:35:07 UTC
- Prior SEC filing
- 11 Jan 2023
- Next SEC filing
- 13 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Young, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 12 Dec 2023.
Change
- Previous filing in this sequence was filed on 11 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKRO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +18,570
- Change %
- Price
- $0.000000
- Shares after
- 18,570
- Date
- 08 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +83,564
- Change %
- Price
- $0.000000
- Shares after
- 83,564
- Date
- 08 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 83,564
- Exercise price
- $19.87
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Footnote F2
This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
SEC remarks
Senior Vice President, Commercial Strategy